Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSC therapy for severe myocardial ischemia
NCT00260338Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2005
- Primary completion
- Jul 2009
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous mesenchymal stem cells in Myocardial ischemia (MI) and coronary heart disease (CHD), sponsored by Rigshospitalet. Primary endpoint: Improvement in myocardial perfusion measured by SPECT at 6 months. Started Dec 2005; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
Myocardial ischemia (MI)coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT00260338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00260338.